These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 19419940)
1. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Hong W; Abi-Raad R; Alomari AK; Hui P; Buza N Hum Pathol; 2015 Jul; 46(7):1000-5. PubMed ID: 25997988 [TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917 [TBL] [Abstract][Full Text] [Related]
4. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912 [TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma. Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545 [TBL] [Abstract][Full Text] [Related]
6. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia. Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080 [TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805 [TBL] [Abstract][Full Text] [Related]
8. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484 [TBL] [Abstract][Full Text] [Related]
9. [KRAS mutations analysis in mucinous epithelial lesions of the endometrium]. Zheng XZ; Zhan Y; Ma JH; Xu HW; Zhi WX; Chen TB; Qin XY; Wang P; Zhang LH; Gu YC; Jin YL; Zhu L; Wu BQ Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):687-690. PubMed ID: 30220122 [No Abstract] [Full Text] [Related]
10. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Koul A; Willén R; Bendahl PO; Nilbert M; Borg A Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059 [TBL] [Abstract][Full Text] [Related]
12. ras gene mutations in human endometrial carcinoma. Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA Oncology; 1996; 53(6):505-10. PubMed ID: 8960147 [TBL] [Abstract][Full Text] [Related]
13. Molecular profiles of benign and (pre)malignant endometrial lesions. van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752 [TBL] [Abstract][Full Text] [Related]
14. Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. Alomari A; Abi-Raad R; Buza N; Hui P Mod Pathol; 2014 May; 27(5):675-80. PubMed ID: 24186144 [TBL] [Abstract][Full Text] [Related]
15. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803 [TBL] [Abstract][Full Text] [Related]
16. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal GP; Parker SL; Kohler MF; Berchuck A Cancer Res; 1993 Apr; 53(8):1906-10. PubMed ID: 8467512 [TBL] [Abstract][Full Text] [Related]
17. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179 [TBL] [Abstract][Full Text] [Related]
18. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Guerra F; Kurelac I; Cormio A; Zuntini R; Amato LB; Ceccarelli C; Santini D; Cormio G; Fracasso F; Selvaggi L; Resta L; Attimonelli M; Gadaleta MN; Gasparre G Hum Mol Genet; 2011 Jun; 20(12):2394-405. PubMed ID: 21470976 [TBL] [Abstract][Full Text] [Related]
19. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910 [TBL] [Abstract][Full Text] [Related]